


**APPENDIX A**

**CLEAN COPY OF CLAIMS AS AMENDED HEREIN**

1. (Currently Amended) A method of treating a disease state in a mammal that is alleviable by treatment with an agent capable of increasing ABCA-1 expression, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the Formula I:



Formula I

wherein:

m, n and p are independently 0 or 1;

A is -C(Z<sup>1</sup>)-, -C(Z<sup>1</sup>)-NH-, SO<sub>2</sub>, or a covalent bond;

where Z<sup>1</sup> is oxygen or sulfur;

R<sup>1</sup> is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R<sup>2</sup> is hydrogen, alkyl, or cycloalkyl; or

R<sup>1</sup>, R<sup>2</sup> and A when taken together with the nitrogen atom to which they are attached form a nitrogen bearing heterocycle;

R<sup>3</sup> is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R<sup>4</sup> is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

T is -O-, -S(O)<sub>q</sub>, or -NR<sup>5</sup>-;

in which q is 0, 1, or 2; and

$R^5$  is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

$X^1$ ,  $X^2$ , and  $X^3$  are nitrogen;

$Y^1$  is lower alkylene or carbonyl;

$Y^2$  is lower alkylene or oxygen; and

Z is sulfur

with the proviso that when A is a covalent bond and  $R^2$  is hydrogen then  $R^1$  cannot be phenyl.

3. (Currently Amended) The method of claim 1, wherein  $R^2$  is hydrogen; and  $R^4$  is optionally substituted alkyl.

4. (Original) The method of claim 3, wherein  $R^3$  is optionally substituted aryl or optionally substituted heteroaryl.

5. (Original) The method of claim 4, wherein m is 0, n is 1, and p is 1.

6. (Original) The method of claim 5, wherein A is a covalent bond, and  $R^1$  is hydrogen.

7. (Original) The method of claim 6, wherein  $R^3$  is optionally substituted phenyl and  $Y^2$  is methylene.

8. (Original) The method of claim 7, wherein  $R^4$  is alkyl of 1-8 carbon atoms and T is oxygen.

9. (Previously Amended) The method of claim 8, wherein  $R^3$  is 4-*t*-butylphenyl and  $R^4$  is methyl, namely 6- $\{[4-(\text{tert-butyl})\text{phenoxy}]\text{methyl}\}$ -4-methylthio-1,3,5-triazine-2-ylamine.


10. (Original) The method of claim 8, wherein R<sup>3</sup> is 4-t-butylphenyl and R<sup>4</sup> is n-pentyl, namely 6-{[4-(tert-butyl)phenoxy]methyl}-4-pentylthio-1,3,5-triazine-2-ylamine.

11. (Original) The method of claim 7, wherein R<sup>4</sup> is alkyl of 1-8 carbon atoms and T is oxygen.

12. (Original) The method of claim 11, wherein R<sup>3</sup> is 3-chlorophenyl, R<sup>4</sup> is methyl, and R<sup>5</sup> is hydrogen, namely 4-[(3-chlorophenylamino)methyl]-6-methylthio-[1,3,5]triazin-2-ylamine.

13. (Original) The method of claim 11, wherein R<sup>3</sup> is 2,4-dimethoxyphenyl, R<sup>4</sup> is methyl, and R<sup>5</sup> is hydrogen, namely N-{[(3,5-dimethoxyphenyl)aminomethyl]}-4-methylthio-1,3,5-triazine-2-ylamine;

28. (Currently Amended) A method for treating a disease or condition in a mammal that can be treated with a compound that elevates serum levels of HDL cholesterol, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula I.



Formula I

wherein:

m, n and p are independently 0 or 1;

A is -C(Z<sup>1</sup>)-, -C(Z<sup>1</sup>)-NH-, SO<sub>2</sub>, or a covalent bond;

where  $Z^1$  is oxygen or sulfur;

$R^1$  is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

$R^2$  is hydrogen, alkyl, or cycloalkyl; or

$R^1$ ,  $R^2$  and A when taken together with the nitrogen atom to which they are attached form a nitrogen bearing heterocycle;

$R^3$  is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

$R^4$  is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

T is -O-, -S(O)<sub>q</sub>, or -NR<sup>5</sup>-;

in which q is 0, 1, or 2; and

$R^5$  is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

$X^1$ ,  $X^2$ , and  $X^3$  are nitrogen;

$Y^1$  is lower alkylene or carbonyl;


$Y^2$  is lower alkylene or oxygen; and

Z is sulfur

with the proviso that when A is a covalent bond and  $R^2$  is hydrogen then  $R^1$  cannot be phenyl.

29. (Original) The method of claim 28, wherein the disease state or condition is coronary artery disease or atherosclerosis.

30. (Currently Amended) A method for treating a disease or condition in a mammal related to low HDL cholesterol levels, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula I:



Formula 1

wherein:

m, n and p are independently 0 or 1;

A is -C(Z<sup>1</sup>)-, -C(Z<sup>1</sup>)-NH-, SO<sub>2</sub>, or a covalent bond;

where Z<sup>1</sup> is oxygen or sulfur;

R<sup>1</sup> is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R<sup>2</sup> is hydrogen, alkyl, or cycloalkyl; or

R<sup>1</sup>, R<sup>2</sup> and A when taken together with the nitrogen atom to which they are attached form a nitrogen bearing heterocycle;

R<sup>3</sup> is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R<sup>4</sup> is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

T is -O-, -S(O)<sub>q</sub>, or -NR<sup>5</sup>-;

in which q is 0, 1, or 2; and

R<sup>5</sup> is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

X<sup>1</sup>, X<sup>2</sup>, and X<sup>3</sup> are nitrogen;

Y<sup>1</sup> is lower alkylene or carbonyl;


Y<sup>2</sup> is lower alkylene or oxygen; and

Z is sulfur

with the proviso that when A is a covalent bond and R<sup>2</sup> is hydrogen then R<sup>1</sup> cannot be phenyl.

31. (Original) The method of claim 30, wherein the disease state or condition is coronary artery disease or atherosclerosis.

32. (Currently Amended) A method for treating a disease or condition in a mammal that can be treated with a compound that promotes cholesterol efflux from cells, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula I.



Formula I

wherein:

m, n and p are independently 0 or 1;

A is -C(Z<sup>1</sup>)-, -C(Z<sup>1</sup>)-NH-, SO<sub>2</sub>, or a covalent bond;

where Z<sup>1</sup> is oxygen or sulfur;

R<sup>1</sup> is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R<sup>2</sup> is hydrogen, alkyl, or cycloalkyl; or

R<sup>1</sup>, R<sup>2</sup> and A when taken together with the nitrogen atom to which they are attached form a nitrogen bearing heterocycle;

R<sup>3</sup> is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

$R^4$  is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

T is -O-, -S(O)<sub>q</sub>, or -NR<sup>5</sup>-;

in which q is 0, 1, or 2; and

$R^5$  is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

$X^1$ ,  $X^2$ , and  $X^3$  are nitrogen;

$Y^1$  is lower alkylene or carbonyl;


$Y^2$  is lower alkylene or oxygen; and

Z is sulfur

with the proviso that when A is a covalent bond and  $R^2$  is hydrogen then  $R^1$  cannot be phenyl.

33. (Original) The method of claim 32, wherein the disease state or condition is coronary artery disease or atherosclerosis.

34. (Currently Amended) A method for treating a condition related to coronary artery disease in a mammal that can be usefully treated with a combination of a compound that elevates serum levels of HDL cholesterol and a compound that lowers LDL cholesterol, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula I



Formula I



wherein:

m, n and p are independently 0 or 1;

A is -C(Z<sup>1</sup>)-, -C(Z<sup>1</sup>)-NH-, SO<sub>2</sub>, or a covalent bond;

where Z<sup>1</sup> is oxygen or sulfur;

R<sup>1</sup> is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R<sup>2</sup> is hydrogen, alkyl, or cycloalkyl; or

R<sup>1</sup>, R<sup>2</sup> and A when taken together with the nitrogen atom to which they are attached form a nitrogen bearing heterocycle;

R<sup>3</sup> is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R<sup>4</sup> is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

T is -O-, -S(O)<sub>q</sub>, or -NR<sup>5</sup>-;

in which q is 0, 1, or 2; and

R<sup>5</sup> is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

X<sup>1</sup>, X<sup>2</sup>, and X<sup>3</sup> are nitrogen;

Y<sup>1</sup> is lower alkylene or carbonyl;

Y<sup>2</sup> is lower alkylene or oxygen; and


Z is sulfur

with the proviso that when A is a covalent bond and R<sup>2</sup> is hydrogen then R<sup>1</sup> cannot be phenyl

and a compound that lowers LDL cholesterol.

35. (Original) The method of claim 34, wherein the LDL cholesterol lowering compound is chosen from clofibrate, gemfibrozil, and fenofibrate, nicotinic acid, mevinolin, mevastatin, pravastatin, simvastatin, fluvastatin, lovastatin, cholestyrene, colestipol and probucol.

36. (Currently Amended) A compound of the Formula I:



Formula I

wherein:

m, n and p are independently 0 or 1;

A is -C(Z<sup>1</sup>)-, -C(Z<sup>1</sup>)-NH-, SO<sub>2</sub>, or a covalent bond;

where Z<sup>1</sup> is oxygen or sulfur;

R<sup>1</sup> is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R<sup>2</sup> is hydrogen, alkyl, or cycloalkyl; or

R<sup>1</sup>, R<sup>2</sup> and A when taken together with the nitrogen atom to which they are attached form a nitrogen bearing heterocycle;

R<sup>3</sup> is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R<sup>4</sup> is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

T is -O-, -S(O)<sub>q</sub>, or -NR<sup>5</sup>-;

in which q is 0, 1, or 2, and R<sup>5</sup> is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

X<sup>1</sup>, X<sup>2</sup>, and X<sup>3</sup> are nitrogen.

Y<sup>1</sup> is lower alkylene or carbonyl;

Y<sup>2</sup> is lower alkylene or oxygen; and

Z is sulfur

with the proviso that

when A is a covalent bond, R<sup>1</sup> and R<sup>2</sup> are both hydrogen, Y<sup>2</sup> is methylene, and R<sup>4</sup> is methyl or ethyl, R<sup>3</sup> cannot be lower alkyl or unsubstituted phenyl; and

when A is a covalent bond, R<sup>1</sup> cannot be substituted phenyl.

38. (Currently Amended) The compound of claim 36, wherein R<sup>2</sup> is hydrogen, and R<sup>4</sup> is optionally substituted alkyl.

39. (Currently Amended) The compound of claim 38, wherein R<sup>3</sup> is optionally substituted aryl or optionally substituted heteroaryl.

40. (Original) The compound of claim 39, wherein m is 0, n is 1, and p is 1.

41. (Original) The compound of claim 40, wherein A is a covalent bond, and R<sup>1</sup> is hydrogen.

42. (Original) The compound of claim 41, wherein R<sup>3</sup> is optionally substituted phenyl and Y<sup>2</sup> is methylene.

43. (Original) The compound of claim 42, wherein R<sup>4</sup> is alkyl of 1-8 carbon atoms and T is oxygen.

44. (Original) The compound of claim 43, wherein R<sup>3</sup> is 4-t-butylphenyl and R<sup>4</sup> is methyl, namely 6-{[4-(tert-butyl)phenoxy]methyl}-4-pentylthio-1,3,5-triazine-2-ylamine.

45. (Original) The compound of claim 43, wherein R<sup>3</sup> is 4-t-butylphenyl and R<sup>4</sup> is n-pentyl, namely 6-{[4-(tert-butyl)phenoxy]methyl}-4-pentylthio-1,3,5-triazine-2-ylamine.

46. (Original) The compound of claim 43, wherein R<sup>3</sup> is 3-chlorophenyl, R<sup>4</sup> is methyl, and R<sup>5</sup> is hydrogen, namely 4-[(3-chlorophenylamino)methyl]-6-methylthio-[1,3,5]triazin-2-ylamine.

47. (Original) The compound of claim 43, wherein R<sup>3</sup> is 2,4-dimethoxyphenyl, R<sup>4</sup> is methyl, and R<sup>5</sup> is hydrogen, namely N-{[(3,5-dimethoxyphenyl)aminomethyl]-4-methylthio-1,3,5-triazine-2-ylamine.

63. (Previously Presented) A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of claim 36.